Lavipharm
Lavipharm (LAVI) closed at €1.518 on 26/10/2026, +4.55% on the day. Market cap €256.6m, P/E 45.0, dividend yield 1.32%.
Why it moved on Mon 26 Oct
No published cause yet.
Key statistics
12 months to Jun 2026 unless a figure says otherwise
Profile
At the 26 Oct close- Market value
- €256.6m
- Enterprise valueDec 2025est.
- €283.2m
- Shares outstandingOct 2026
- 169m
- Revenue12 months to Jun 2026
- €77.7m
- Employees
- 306
- Free floatest.
- 38.1%
- Traded a day, 3-month average
- €134.5k
Valuation
12 months to Jun 2026- P/EFY2021
- 45.0×
- P/B
- 4.5×
- EV/Salesest.
- 3.6×
- EV/EBITDAest.
- 19.0×
- P/FCFFY2025
- 125.4×
- Dividend yield
- 1.3%
5 years, on reported full years: 9.8–30.6×, median 17.9×. Today 18.3×, higher than 55% of months.
Margins
FY2025- Gross
- 43.3%
- EBITDA12 months to Jun 2026
- 19.2%
- Operating (EBIT)
- 13.4%
- Pre-taxFY2023
- 5.8%
- Net
- 8.6%
- Free cash flow
- 2.9%
Net margin = the shareholders' profit ÷ group revenue.
Returns
FY2025- ROE
- 11.0%
- ROCE
- 11.3%
- ROICest.
- 6.8%
- ROA
- 4.6%
- ROE, 5-year averageFY2021–25
- 9.9%
- Tax rateFY2023
- 39.9%
Financial health
Dec 2025- CashDec 2023
- €8.4m
- Net debt
- €26.6m
- Net debt ÷ EBITDA
- 1.8×
- Debt ÷ equity
- 57.9%
- Interest coverFY2025
- 5.1×
leases included
Growth
- Revenue, last yearFY2025
- +14.8%
- Revenue, last halfH1 2026
- +28.8%
- Revenue, 3 yearsFY2022–25, a year
- +15.8%
- Revenue, 5 yearsFY2020–25, a year
- +13.2%
Dividends
FY2025- Yield, last 12 months
- 1.3%
- Per share
- €0.020
- Covered by free cash flow
- 0.61×
- Years paid, last fiveFY2021–25
- 2
Trading and risk
From our closes, dividends reinvested- Total return, 1 year
- +91.2%
- 3 years, a year
- +37.3%
- 5 years, a year
- +7.2%
- 10 years, a year
- +20.3%
- Volatility, 1 year
- 38.7%
- Beta to the General Index
- 1.02×
- Deepest fall, 1 year / 5 years
- −25.5% / −83.3%
- 52-week range
- €0.800–€1.704
Where the figures come from: the company's reports, reviewed by us · annual accounts filed in ESEF format · results announcements on the exchange · our own closing prices. No forecasts or target prices are stored.
Financial charts
From the stored figures: the reviewed dossier first, then the annual reports (ESEF) and results announcements
Loading the charts…
Valuation
no like-for-like peer| Metric | LAVI |
|---|---|
| P/E | 45.0 |
| P/B | 4.5 |
| P/S | 3.3 |
| EV/EBITDA | 19.0 |
| Dividend yield | 1.3% |
| Gross margin | 43.3% |
| Operating margin | 13.4% |
| Net margin | 8.6% |
| ROE | 11.0% |
| Revenue growth (last full year) | 14.8% |
| Net debt | €26.6m |
Peers: Pharmaceuticals
No other company listed in Athens runs this business.
The company
AI-draftedLavipharm makes and sells medicines. In Greece it supplies prescription drugs, consumer healthcare products and medical cannabis to pharmacies through wholesalers, at state-set reimbursed prices. At its Paiania factory it manufactures transdermal patches, mostly fentanyl, which it exports to pharmaceutical partners. The Lavidas family controls it.
- Sep 2026H1 2026 interim reported €34.44m IFRS revenue, €7.08m continuing EBITDA and €37.7m net debt.7,8
- Jun 2026The annual general meeting approved a dividend of €0.02 per share for FY2025.1
- Apr 2026Agreement with Janssen to acquire the DUROGESIC rights in 24 countries for USD 12m.3
- Dec 2025Sale of the Pylaia investment property in Thessaloniki for €1.93m.3
- Jul 2025Dividend of €0.02 per share for FY2024 and 352,524 free shares issued to two executives.3
- Jan 2025The sale of Pharma Plus to Diorama Investments II completed, with a €0.97m gain.3
- The USD 12m DUROGESIC rights deal covers 24 countries; licences had transferred in key markets, with distribution expected from October 2026.7,8
- Dividend of €0.02 per share for FY2025, the second in a row, timetabled for payment on 24 July 2026.1,6
- One customer takes more than 10% of group revenue and is not named.3
- Exercise of 1,734,922 options in May 2026 lifted shares outstanding to 170,778,483.7
- 285 employees at end-2025 and one factory at Paiania, held under a sale and leaseback to 2039.3
- 1.Annual General Meeting of Shareholders 2026, press releaseLavipharm S.A. · 25/06/2026official
- 2.Annual Analysts Update presentation, Athens ExchangeLavipharm S.A. · 27/04/2026official
- 3.Annual Financial Report 2025Lavipharm S.A. · 23/04/2026official
- 4.Flash Note, Annual Financial Results 2024Lavipharm S.A. · 19/03/2025official
- 5.Shareholders' Structure pageLavipharm S.A.official
- 6.Financial Calendar 2026Lavipharm S.A. · 05/03/2026official
- 7.H1 2026 reviewed Interim Financial ReportLavipharm S.A. / Euronext Athens · 17/09/2026official
- 8.H1 2026 Financial Results announcementLavipharm S.A. · 17/09/2026official